Contemporary Oncology
Overview
Contemporary Oncology is a scientific journal, published by Termedia since 1997 in English and Polish. The journal's country of origin is Poland and its primary focus area is oncology.
Details
Details
Metrics
Metrics
h-index / Ranks: 10268
31
SJR / Ranks: 8458
532
CiteScore / Ranks: 9809
2.40
Recent Articles
1.
Sikora J, Blaszkiewicz P, Dudkowiak A, Jagielska J, Zurawski J
Contemp Oncol (Pozn)
. 2025 Feb;
28(4):326-334.
PMID: 39935760
Introduction: Gold nanoparticles (AuNPs) have unique properties that promise new and improved methods for targeting cancer treatment and diagnosis. However, despite their relatively high biocompatibility, AuNPs can negatively affect cell...
2.
Torounidou N, Yerolatsite M, Zarkavelis G, Amylidi A, Karafousia V, Kampletsas E, et al.
Contemp Oncol (Pozn)
. 2025 Feb;
28(4):283-290.
PMID: 39935759
Metastatic colorectal cancer (mCRC) remains a significant challenge in contemporary oncology, with treatment sequencing playing a pivotal role in reported patient outcomes. Although currently available therapeutic options have led to...
3.
Krajewski W, Guzinski M, Laszkiewicz J, Tomczak W, Chelmonski A, Grunwald K, et al.
Contemp Oncol (Pozn)
. 2025 Feb;
28(4):335-340.
PMID: 39935758
Introduction: Partial nephrectomy (PN) is the primary treatment for T1 renal cell carcinoma (RCC). Also, percutaneous cryoablation is gaining attention as a curative option in appropriately selected patients. However, even...
4.
Fojnica A, Gromilic Z, Ali Mohamed Y, Akhtar S, Vranic S
Contemp Oncol (Pozn)
. 2025 Feb;
28(4):271-282.
PMID: 39935757
Cyclosporine A (CsA) is widely used as an immunosuppressant in organ transplantation to improve graft survival and prevent tissue rejection. The impact of CsA on cancer progression is highly complex,...
5.
Solek J, Nowicka Z, Fendler W, Sadej R, Romanska H, Braun M
Contemp Oncol (Pozn)
. 2025 Feb;
28(4):341-349.
PMID: 39935756
Introduction: Fibroblast growth factor receptor 2 (FGFR2) activation is associated with endocrine therapy resistance in luminal breast cancer (BC) , but clinical evidence remains inconsistent. Given the role of FGFRs...
6.
Szewczyk M, Ostapowicz J, Piotrowski I, Ostrowska K, Suchorska W, Golusinski W
Contemp Oncol (Pozn)
. 2025 Feb;
28(4):291-296.
PMID: 39935755
Introduction: Despite advances in diagnostics and therapy, the 5-year mortality rate of oral squamous cell cancer (OSCC) remains at about 50%. Prognostic molecular biomarkers are not yet approved for clinical...
7.
Ayeldeen G, Zaki A, Amer E, Abdellatif Z, Shaker O, Said M, et al.
Contemp Oncol (Pozn)
. 2025 Feb;
28(4):304-317.
PMID: 39935754
Introduction: Patients with colorectal cancer (CRC) have a higher chance of survival when the disease is detected and treated effectively at an early stage. Plasmacytoma variant translocation 1 (PVT-1), an...
8.
Arraras J, Illarramendi J, Manterola A, Zarandona U, Ibanez B, Bottomley A, et al.
Contemp Oncol (Pozn)
. 2025 Feb;
28(4):350-357.
PMID: 39935753
Introduction: Metastatic breast cancer (MBC) can profoundly impact patients' lives. The health-related quality of life (HRQOL) of MBC metavivors remains a paramount concern. This study exa-mined the multifaceted aspects of...
9.
Zok J, Bienkowski M, Radecka B, Kuchar A, Borowiec S, Streb J, et al.
Contemp Oncol (Pozn)
. 2025 Feb;
28(4):297-303.
PMID: 39935752
Introduction: The BRAF mutation is found in 6-11% of metastatic colo-rectal cancer (mCRC) patients. According to international guidelines for BRAF-mutated mCRC, the triplet chemotherapy FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin, irinotecan)...
10.
Laliscia C, Perrone F, Guido F, Cresti F, Fuentes T, Paiar F, et al.
Contemp Oncol (Pozn)
. 2025 Feb;
28(4):318-325.
PMID: 39935751
Introduction: This study reports the long-term outcomes in patients affected by uveal melanoma (UM) treated with ruthenium-106 (Ru) plaque bra-chytherapy (BT). Material And Methods: From May 2005 to January 2024,...